Across TCGA pan-cancer cohorts, LY6G6F Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated LY6G6F data layer compared with 16 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher LY6G6F Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LY6G6F expression acts as an unfavorable survival marker.

OV are the cancer types where LY6G6F Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.282	0.692	.014	18	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: LY6G6F tumor-vs-normal RNA expression · all LY6G6F data types